We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Largest Scanner Ever Developed to Produce Faster, More Sensitive Images

By Biotechdaily staff writers
Posted on 03 Mar 2008
One of the world's largest imagers has been developed that could form the basis of future medical scanners. More...
The new technology will allow clinicians to produce more sensitive and faster images of the human body at a lower cost to healthcare professionals.

The innovative technology, which has been developed by engineers from the University of Sheffield (UK) and Science & Technology Facilities Council (STFC) Rutherford-Appleton Laboratories (Didcot, UK), as part of the £4.5m Basic Technology MI-3 Consortium, will help in providing instant analysis of medical screening tests and the early detection of cancer.

Easier to use and faster than the imagers used in current body scanners, and with very large active pixel sensors with an imaging area of approximately 6-cm2, the technology has been specifically developed to meet demanding clinical applications such as X-ray imaging and mammography. This silicon imager is approximately 15 times larger in area than the latest Intel processors.

The next step of the project is to produce wafer-scale imagers that can produce images approaching the width of the human torso. This will eliminate the need for expensive and inefficient lenses and in that way enable lower-cost, more sensitive, and faster medical imaging systems.

Prof. Nigel Allinson, from the University of Sheffield's Vision and Information Engineering Group in the department of electronic and electrical engineering and who led the project, said, "Very large active pixel sensors could soon be making a major impact on medical imaging by further reducing the need for the old technology of film. The UK is a world-lead in such sensors for scientific and medical applications, and this is a lead we intend to maintain.”

Dr. Renato Turchetta, leader of the design team, added, "Wafer-scale CMOS [complementary metal oxide semiconductor] sensors are now a reality and the team is ready to take the digital revolution a step further in order to revolutionize scientific and medical imaging.”

MI-3 is a four-year £4.5 million project funded by the UK Research Council Basic Technology program. The consortium consists of leading groups in detector technology, microelectronics, particle physics, space science, biosciences, and medical physics at universities throughout the United Kingdom.

These sensors were developed by the CMOS Sensor Design Group at STFC's Rutherford Appleton Laboratory in association with the University of Sheffield and University College London.


Related Links:
University of Sheffield
Science & Technology Facilities Council Rutherford-Appleton Laboratories

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.